Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag with azacitidine for thrombocytopenia in myelodysplastic syndromes
ACTRN12610000641099Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Nov 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eltrombopag and azacitidine in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Grade III/IV non-haematological toxicity related to eltrombopag and azacitidine. Started Nov 2010; status: recruiting.
02
Drugs
eltrombopagazacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ACTRN12610000641099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000641099.